簡介:安帕來斯,Ampalex是AMPA受體陽性變構(gòu)調(diào)節(jié)劑,可作用于阿爾茨海默病,精神分裂等。
安帕來斯物理化學(xué)性質(zhì):
密度 |
1.2±0.1 g/cm3 |
沸點 |
433.1±25.0 °C at 760 mmHg |
熔點 |
88-90oC |
分子式 |
C14H15N3O |
分子量 |
241.288 |
閃點 |
215.8±23.2 °C |
精確質(zhì)量 |
241.121506 |
PSA |
46.09 |
LogP |
0.57 |
外觀性狀 |
黃褐色固體 |
蒸汽壓 |
0.0±1.0 mmHg at 25°C |
折射率 |
1.64 |
安帕來斯詳細(xì)介紹:
中文名稱: |
安帕來斯 |
中文別名: |
安帕來斯;1-(喹喔啉-6-基甲?;?哌啶;安帕萊斯;6-1-(喹喔啉基-6-羰基)-哌啶;安帕來斯 1G |
英文名稱: |
Ampalex |
英文別名: |
Piperidin-1-yl(quinoxalin-6-yl)methanone;1-(Quinoxalin-6-ylcarbonyl)piperidine;Piperidin-1-yl-quinoxalin-6-ylmethanone;Ampalex;ABT-224;Ampakine CX516;BDP 12;CX516;CX-516;PIPERIDINE, 1-(6-QUINOXALINYLCARBONYL)-;1-Piperidinyl-6-quinoxalinyl-methanone;6-(Piperidin-1-ylcarbonyl)quinoxaline;AMpalex (CX-516);SPD-420, BDP-12, CX-516, AMpalex;1-(6-Quinoxalinylcarbonyl)piperidine;1-Piperidinyl-6-quinoxalinylMethanone;BDP-12;BDP-12;;CX 516;Ampalex, >=98%;6-(piperidine-1-carbonyl)quinoxaline;1-piperidyl(quinoxalin-6-yl)methanone;Z5QU38B4V9;Piperidin-1-yl-quinoxalin-6-yl-methanone;1-(6-quinoxalinylcarbonyl)-Piperidine;PubChem |
CAS號: |
154235-83-3 |
分子式: |
C14H15N3O |
分子量: |
241.29 |
詳細(xì)描述: |
博飛美科提供154235-83-3,安帕來斯,Ampalex,Perfemiker,上?,F(xiàn)貨。 Medlife,致力于提供高品質(zhì)、高性價比小分子化合物的產(chǎn)品。 Medlife小分子化合物大量庫存,提供超過2萬種的抑制劑、激動劑、拮抗劑等產(chǎn)品,是藥物及疾病研究的重要原料供應(yīng)商。 促智藥,Ampalex (Ampakine CX516; CX516; BDP 12)是AMPA受體陽性變構(gòu)調(diào)節(jié)劑,可作用于阿爾茨海默病,精神分裂等。 查詢關(guān)鍵詞:“154235-83-3,安帕來斯,Ampalex,PC11861,Perfemiker,上?,F(xiàn)貨”。 |
安帕來斯參考文獻:
[1]. Broberg BV, Glenth?j BY, Dias R, et al. Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology (Berl). 2009
[2]. Kanju PM, Parameshwaran K, Sims C, et al. Ampakine CX516 ameliorates functional deficits in AMPA receptors in a hippocampal slice model of protein accumulation. Exp Neurol. 2008 Nov;214(1):55-61.
[3]. Goff DC, Lamberti JS, Leon AC, et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2008 Feb;33(3):465-72.
[4]. O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets. 2007 May;8(5):603-20.
[5]. Johnson SA, Simmon VF. Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report. J Mol Neurosci. 2002 Aug-Oct;19(1-2):197-200.